Clinical Trial

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

Name: Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. — clinical trial record (NCT07421856)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma

Trial Details

NCT Number	NCT07421856
Lead Sponsor	Hebei Senlang Biotechnology Inc., Ltd. Collaborators: Peking University People's Hospital, Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma in Relapse, Multiple Myeloma Refractory
Enrollment	24 participants
Start Date	2026-02-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-19